FDA Adverse Event Injury Summary report: N

NG PROMUS

MDR report key: 3072863 · Received April 23, 2013

Report

Report Number
2134265-2013-02459
Event Type
Injury
Date Received
April 23, 2013
Date of Event
December 13, 2012
Report Date
March 25, 2013
Manufacturer
BOSTON SCIENTIFIC - MAPLE GROVE
Product Code
NIQ
PMA / PMN Number
P110010
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
NZ
Reporter Occupation
PHYSICIAN

Narratives

Additional Manufacturer Narrative · 1

DEVICE IS A COMBINATION PRODUCT. DEVICE EVALUATED BY MFR: IT IS INDICATED THAT THE DEVICE WILL NOT BE RETURNED FOR EVALUATION; THEREFORE A FAILURE ANALYSIS OF THE COMPLAINT DEVICE COULD NOT BE COMPLETED. A REVIEW OF THE BATCH HISTORY, HISTORICAL TRENDING, AND SIMILAR COMPLAINT TRENDING REVIEW FOR THE PRODUCT FAMILY WILL BE CONDUCTED. IF THERE IS ANY FURTHER INFORMATION FROM THAT REVIEW, A SUPPLEMENTAL MEDWATCH WILL BE FILED. (B)(4).

Description of Event or Problem · 1

(B)(4) STUDY. IT WAS REPORTED THAT FOLLOWING A CORONARY ARTERY STENTING TREATMENT PROCEDURE, SIDE BRANCH STENOSIS WAS NOTED. IN (B)(6) 2012, CLINICAL STATUS ASSESSMENT IDENTIFIED THE PATIENT'S QUALIFYING CONDITION AS UNSTABLE ANGINA (CCS CLASS II) AS WELL AS ABNORMAL FRACTIONAL FLOW RESERVE (FFR) INDICATING ISCHEMIA PRIOR TO THE PROCEDURE. THE PATIENT WAS REFERRED FOR CARDIAC CATHETERIZATION. THE TARGET LESION WAS LOCATED IN THE MID LEFT ANTERIOR DESCENDING ARTERY (MID LAD) WITH 50% STENOSIS AND WAS 10MM LONG WITH A REFERENCE VESSEL DIAMETER OF 2.5MM. THE TARGET LESION WAS TREATED WITH PRE-DILATION AND PLACEMENT OF A 2.50X20MM NG PROMUS STENT, WITH 0% RESIDUAL STENOSIS FOLLOWING POST-DILATION. THE PATIENT WAS DISCHARGED ON ASPIRIN AND CLOPIDOGREL. THE CORE LAB REPORTED 0% SIDE BRANCH STENOSIS PER THE BASELINE INDEX ANGIOGRAPHY AND 70% SIDE BRANCH STENOSIS PER THE POST-PROCEDURE ANGIOGRAPHY.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
175205 NG PROMUS STENT, CORONARY, DRUG-ELUTING NIQ BOSTON SCIENTIFIC - MAPLE GROVE H7493925020250 15490100

Patients

Seq Age Sex Outcome Treatment
1 71 YR Other